De Novo Ventures
Boston · 2 people tracked
Team · 2 people
from public directoriesFund performance · per public LP disclosures · 4
as of Jun 2020| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| De Novo Ventures IIILPs: The Regents of the University of California | 2006 | — | -9.8% | 0.69x | 0.69x |
| De Novo Ventures III, L.PLPs: The Regents of the University of California | 2006 | — | -9.8% | 0.69x | 0.69x |
| De Novo Ventures IILPs: The Regents of the University of California | 2003 | — | -13.3% | 0.40x | 0.40x |
| De Novo Ventures II, L.PLPs: The Regents of the University of California | 2003 | — | -13.3% | 0.40x | 0.40x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- Where is De Novo Ventures located?
- De Novo Ventures is headquartered in Boston, US.
Co-investors · 6
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Longwood Fund is a Boston-based venture firm focused on discovering and building science-based companies, with a team spanning doctors, scientists, entrepreneurs, and investors.
Firms observed investing alongside De Novo Ventures, from public investor directories. Shared companies are the overlap with De Novo Ventures's recorded portfolio.